---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-227921"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2026-05-18T12:00:43+00:00"
generated_at: "2026-05-18T12:07:56.332422+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026

## Summary
- ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
- Blinded liver histology: ALN1003-treated mice had mean NAS scores of 2.7 and 1.3 vs control score of 5.
- Data are from non-GLP studies with small sample sizes; no human trials conducted yet.
- Cash and equivalents $0.354M as of March 31, 2026; company seeking additional financing.
- Plans to advance ALN1003 with further preclinical dose optimization and metabolic phenotyping.

## SEC filing metadata
- accession: 0001193125-26-227921
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2026-05-18T12:00:43+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/0001193125-26-227921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/tcrt-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-227921
- JSON: https://secwatch.observer/filing/0001193125-26-227921.json
- Plain text: https://secwatch.observer/filing/0001193125-26-227921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.